Our findings provide the first demonstration of the stronger contribution of monocyte CD163 levels in the peripheral blood compared to the serum sCD163 level for insulin resistance in patients with type 2 diabetes, suggesting the possibility of its use as a novel clinical surrogate marker for insulin resistance and providing new insight into the role of CD163 in insulin resistance and inflammation. This evidence concerns the gene CD163 and type 2 diabetes mellitus.